The Procter Gamble Company

The Cleveland Clinic Foundation

Alimentary Health Limited

Precisionbiotics Group Limited

Jose Carlos Garcia-Garcia

Stanley Leon Hazen

George Franklin Gerberick

John August Wos

Michael Reilly

Xiaodong Gu

David Blair Cody

Liam Diarmuid O'Mahony

Barry Kiely

David Thomas Stanton

Michael John Janusz

Eileen Frances Murphy

Thomas Alfred Inglin

Angela Jane Deutsch

Jodie Michelle Reed

Jodie Michele Reed

Mark Robert Sivik

Dimitris Ioannis Collias

Martin Ian James

Raul Victorino Nunes

Freddy Arthur Barnabas

Gary Wayne Gilbertson

Nicholas William Geary

Arsen Arsenov Simonyan

John Andrew McDaniel

Yiping Sun

Safa Motlagh

Brian Wilson Howard

Lori Ann Reinsalu

Jeffrey Alan Henry

Vincent Peter Sica

Timothy R Baker

Liam O'mahony

Xiandong Gu

Poly(acrylic acid)-based superabsorbent polymer (SAP) in a feed stream is converted into poly(acrylic acid) (PAA) in an extensional flow device. The total energy used to degrade the SAP into PAA is less than about 50 MJ/kg SAP.

Recycling of superabsorbent polymer with an extensional flow device

A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual by providing a composition comprising (2-hydroxyethyl) dimethylsulfonium with a counterion wherein the counterion is selected from chloride, bromide or iodide.

Methods for inhibiting conversion of choline to trimethylamine (TMA)

A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO by providing a composition comprising a compound set forth in Formula (I): 

A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual by providing a composition comprising a compound set forth in Formula (I): 

The invention provides a method of inhibiting the conversion of carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): Wherein the compound is administered in an amount effective to inhibit conversion of carnitine to TMA in the individual.

Methods for inhibiting conversion of carnitine to trimethylamine (TMA)

The invention provides one or more methods of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual one or more compositions comprising a compound set forth in Formula (I): wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline in the individual.

A formulation comprising an ingestible carrier and an isolated strain of

[object Object]

The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I): The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.

Compounds and methods for inhibiting production of trimethylamine

The disclosure relates to topical compositions and methods comprising whole, non-viable Micrococcaceae cells, wherein the cells have been processed to kill the cells while minimizing lysis. The topical compositions and methods are useful for decreasing skin inflammation and improving skin barrier function.

Compositions and methods for improving skin health

Growing community of inventors

Cincinnati, OH, United States of America

Jose Carlos Garcia-Garcia